Europe Pharma ADMET Testing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Testing Type (In Vivo ADMET Testing, In Vitro ADMET Testing, and In Silico ADMET Testing), Technology (Cell Culture, High Throughput, Molecular Imaging, and OMICS Technology), and Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others)
The pharma ADMET testing market in Europe is expected to grow from US$ 2,199.98 million in 2022 to US$ 3,971.68 million by 2028. It is estimated to grow at a CAGR of 10.3% from 2022 to 2028.
Companies in the pharmaceuticals and biotechnology industries focus on the expansion of their research & development capabilities and drug manufacturing capacity. Rapid developments in computational software and the introduction of novel field technologies are estimated to raise the efficiency of drug development during the forecast period. For instance, toxicity, cytochrome p450 induction, and in vitro metabolism assays, among others, are being incorporated into a single assay on liver hepatocytes. Similarly, 3D cell culture models with multiple tissue cell types are emerging as promising systems.
Moreover, microfluidic organ-on-a-chip approaches, such as those commercialized by Emulate, are becoming more mainstream for predictive ADMET studies. ADMET Predictor by Simulations Plus, Inc., ADME/Tox by Sigma-Aldrich, LLC., PhysChem and ADME-Tox Prediction by ACD/Labs, PK/PD Database for Pharmacokinetic Properties by the Laboratory of Computational and Medicinal Chemistry, etc., are several tools developed for predicting toxicity related to ADME. Artificial intelligence (AI) may be used to simulate the ADME of drugs, determine if a therapeutic molecule will be effective in humans, and predict safety concerns.
During the period of post-COVID recovery, the current popularity and concurrent emergence of AI and machine learning (ML) are likely to have a substantial impact on drug design and development. These technologies have decreased the need for human intervention and raised the quality of life of people as they can be implemented in designing superior-quality healthcare goods. With the help of specialized molecular modeling techniques, such as in-silico simulation, pharmacophore modeling, molecular dynamics, virtual screening, and molecular docking, AI&ML-driven rational drug design seeks to explain the unforeseen bioactivity of natural products most perfectly in a limited timeframe.
Additionally, it describes the molecular interaction of drugs and their targets to create more effective drug leads. In January 2022, Charles River Laboratories and Valo Health, LLC, a technology firm leveraging human-centric data and AL-based computing, established a multi-year strategic collaboration to change the drug research & development process. A new revolutionary, AI-enabled drug discovery and development platform will be made available through this partnership by using Charles River's discovery optimization capabilities, including medicinal chemistry, ADME, biology, and pharmacology, and Valo's Opal Platform for small molecule development, which utilizes a "closed-loop" in a silico-experimental platform that rapidly iterates using program data to identify novel compounds. Thus, ADME testing based on automation, AI, and ML, among other technologies, is becoming an important part of the digital health boom, providing significant growth opportunities for the Pharma ADMET testing market.
Europe Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)
Europe Pharma ADMET Testing Market Segmentation
The Europe pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment is dominating the market in 2022. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment is dominating the market in 2022. Based on application, the market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is dominating the market in 2022. Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Further, the Rest of Europe dominated the market in 2022.
A few key players dominating the Europe pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; CMIC HOLDINGS Co., LTD; Cyprotex Limited; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Pharma ADMET Testing Market – By Testing Type
1.3.2 Europe Pharma ADMET Testing Market – By Technology
1.3.3 Europe Pharma ADMET Testing Market – By Application
1.3.4 Europe Pharma ADMET Testing Market – By Country
2. Europe Pharma ADMET Testing Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pharma ADMET Testing Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Europe Pharma ADMET Testing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Rate of Late-Stage Drug Failure
5.1.2 Rising Number of Product Approvals and Launches
5.2 Market Restraints
5.2.1 High Cost of ADME Testing Studies
5.3 Market Opportunities
5.3.1 Automation and Advancements in ADME Testing
5.4 Future Trends
5.4.1 The Advent of High-Throughput Screening
5.5 Impact Analysis
6. Pharma ADMET Testing Market– Europe Analysis
6.1 Europe Pharma ADMET Testing Market Revenue Forecast and Analysis
7. Europe Pharma ADMET Testing Market– By Testing Type
7.1 Overview
7.2 Europe Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)
7.3 In Vivo ADMET Testing
7.3.1 Overview
7.3.2 In Vivo ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
7.4 In Vitro ADMET Testing
7.4.1 Overview
7.4.2 In Vitro ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
7.5 In Silico ADMET Testing
7.5.1 Overview
7.5.2 In Silico ADMET Testing - Revenue and Forecast to 2028 (US$ Million)
8. Europe Pharma ADMET Testing Market– By Technology
8.1 Overview
8.2 Europe Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)
8.3 Cell Culture
8.3.1 Overview
8.3.2 Cell Culture - Market Revenue and Forecast to 2028 (US$ Million)
8.4 High Throughput
8.4.1 Overview
8.4.2 High Throughput - Market Revenue and Forecast to 2028 (US$ Million)
8.5 Molecular Imaging
8.5.1 Overview
8.5.2 Molecular Imaging - Market Revenue and Forecast to 2028 (US$ Million)
8.6 OMICS Technology
8.6.1 Overview
8.6.2 OMICS Technology - Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Pharma ADMET Testing Market– By Application
9.1 Overview
9.2 Europe Pharma ADMET Testing Market, By Application 2022 & 2028 (%)
9.3 Systemic Toxicity
9.3.1 Overview
9.3.2 Systemic Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.4 Renal Toxicity
9.4.1 Overview
9.4.2 Renal Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Hepatotoxicity
9.5.1 Overview
9.5.2 Hepatotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.6 Neurotoxicity
9.6.1 Overview
9.6.2 Neurotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others - Revenue and Forecasts to 2028 (US$ Million)
10. Europe Pharma ADMET Testing Market– Country Analysis
10.1 Europe: Pharma ADMET Testing Market
10.1.1 Overview
10.1.2 Europe: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)
10.1.2.1 Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.1 Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.2 Germany: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.3 Germany: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.1.4 Germany: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2 UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.1 UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.2 UK: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.3 UK: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.2.4 UK: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3 France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.1 France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.2 France: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.3 France: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.3.4 France: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4 Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.1 Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.2 Italy: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.3 Italy: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.4.4 Italy: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5 Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.1 Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.2 Spain: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.3 Spain: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.5.4 Spain: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6 Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.1 Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.2 Rest of Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.3 Rest of Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
10.1.2.6.4 Rest of Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
11. Europe Pharma ADMET Testing Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 CMIC HOLDINGS Co., LTD
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Charles River Laboratories
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 WuXi AppTec
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Promega Corporation
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sigma-Aldrich (MERCK KGaA)
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Agilent Technologies, Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Biovia (Dassault Systèmes)
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Cyprotex Limited
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Bio-Rad Laboratories, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 IQVIA Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Pharma ADMET Testing Market –Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Germany: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 4. Germany: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 5. UK: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. UK: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 7. UK: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. France: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. France: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 10. France: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 11. Italy: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 12. Italy: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 13. Italy: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 14. Spain: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Spain: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 16. Spain: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Europe: Pharma ADMET Testing Market, by Testing Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Europe: Pharma ADMET Testing Market, by Technology– Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Europe: Pharma ADMET Testing Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments Done by Companies
Table 21. Inorganic Developments Done by Companies
Table 22. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Pharma ADMET Testing Market Segmentation
Figure 2. Europe Pharma ADMET Testing Market, By Country
Figure 3. Europe Pharma ADMET Testing Market Overview
Figure 4. In vivo ADMET Testing Segment Held Largest Share of Testing Type Segment in Europe Pharma ADMET Testing Market
Figure 5. Rest of Europe is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Expert Opinion
Figure 8. Europe Pharma ADMET Testing Market Impact Analysis of Driver and Restraints
Figure 9. Europe Pharma ADMET Testing Market– Revenue Forecast and Analysis – 2022 - 2028
Figure 10. Europe Pharma ADMET Testing Market, by Testing Type 2022 & 2028 (%)
Figure 11. In Vivo ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. In Vitro ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 13. In Silico ADMET Testing - Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe Pharma ADMET Testing Market, by Technology 2022 & 2028 (%)
Figure 15. Cell Culture - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16. High Throughput - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Molecular Imaging - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. OMICS Technology - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Pharma ADMET Testing Market, by Application 2022 & 2028 (%)
Figure 20. Systemic Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Renal Toxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Hepatotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Neurotoxicity - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Others - Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Europe: Pharma ADMET Testing Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26. Europe: Pharma ADMET Testing Market, by Country, 2022 & 2028 (%)
Figure 27. Germany: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. UK: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. France: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Italy: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Spain: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Rest of Europe: Pharma ADMET Testing Market – Revenue and Forecast to 2028 (US$ Million)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Biovia (Dassault Systèmes)
- Charles River Laboratories
- CMIC HOLDINGS Co., LTD
- Cyprotex Limited
- IQVIA Inc.
- MERCK KGaA
- Promega Corporation
- Wuxi AppTec
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe pharma ADMET testing market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe pharma ADMET testing market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the pharma ADMET testing market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution